Signal transduction pathways regulating cyclooxygenase-2 expression: Potential molecular targets for chemoprevention

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 1089-1100

  Chun, Kyung Soo ^a   Surh, Young Joon ^a  

^a Seoul National University   (South Korea)

Author keywords

c Jun N terminal kinase stress activated protein kinase; COX; cyclooxygenase; ERK; extracellular signal regulated kinase; JNK SAPK; MAPK; MEK1 2; mitogen activated protein kinase; nonsteroidal anti inflammatory drugs; NSAIDs; PG; prostaglandin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; CCAAT ENHANCER BINDING PROTEIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOXYCYCLINE; EFLORNITHINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (9 FLUORENYLMETHYLOXYCARBONYL)LEUCINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

CANCER; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL HEMORRHAGE; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTE DYSFUNCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSCRIPTION, GENETIC;

EID: 4143124753     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.05.031     Document Type: Conference Paper

References (166)

1. Greenwald P. From carcinogenesis to clinical interventions for cancer prevention. Toxicology. 166(1-2):2001;37-45
2. Kelloff G.L. Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. 78:2000;199-334
3. DuBois R.N., Smalley W.E. Cyclooxygenase, NSAIDs, and colorectal cancer. J. Gastroenterol. 31:1996;898-906
4. Winde G., Schmid K.W., Brandt B., Muller O., Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis. Colon Rectum. 40:1997;1156-1168
5. Feng L., Sun W., Xia Y., Tang W.W., Chanmugam P., Soyoola E., et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch. Biochem. Biophys. 307:1993;361-368
6. Bennett A., Carter R.L., Stamford I.F., Tanner N.S. Prostaglandin-like material extracted from squamous cell carcinomas of the head and neck. Br. J. Cancer. 41:1980;204-208
7. Bennett A., Carroll M.A., Stamford I.F., Whimster W.F., Williams F. Prostaglandins and human lung carcinomas. Br. J. Cancer. 46:1982;888-893
8. Jung T.T.K., Berlinger N.T., Juhn S.K. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope. 95:1985;307-312
9. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
10. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188
11. Goodwin J.S., Ceuppens J.L. Regulation of immune response by prostaglandins. J. Clin. Immunol. 3:1983;295-315
12. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell. 83:1995;493-501
13. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori H., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716
14. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:2000;1589-1594
15. Boolbol S.K., Dannenberg A.J., Chadburn A., Martucci C., Guo X.J., Ramonetti J.T., et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56:1996;2556-2560
16. Castonguay A., Rioux N. Inhibition of lung tumorigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis. 18:1997;491-496
17. Funkhouser E.M., Sharp G.B. Aspirin and reduced risk of esophageal carcinoma. Cancer. 76:1995;1116-1119
18. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willett W.C., et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:1995;609-614
19. Oshima M., Murai N., Kargman S., Arguello M., Luk P., Kwong E., et al. Chemoprevention of intestinal polyposis in Apc delta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61:2001;1733-1740
20. Rao C.V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V., et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55:1995;1464-1472
21. Reddy B.S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug during different stages of rat colon tumor development. Cancer Res. 47:1987;5340-5346
22. Schreinemachers D.M., Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 5:1994;138-146
23. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1993;1313-1316
24. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., Smith E., et al. Over-expression of COX-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276:2001;18563-18569
25. Neufang G., Furstenberger G., Heidt M., Marks F., Muller-Decker K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc. Natl. Acad. Sci. U.S.A. 98:2001;7629-7634
26. Oshima H., Oshima M., Inaba K., Taketo M.M. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 23:2004;1669-1678
27. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2. Cell. 87:1996;803-809
28. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60:2000;4705-4708
29. Tiano H.F., Loftin C.D., Akunda J., Lee C.A., Spalding J., Sessoms A., et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62:2002;3395-3401
30. Bol D.K., Rowley R.B., Ho C.P., Pilz B., Dell J., Swerdel M., et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res. 62:2002;2516-2521
31. Dannenberg A.J. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2:2001;544-551
32. Shao J. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 275:2000;33951-33956
33. Marks F., Muller-Decker K., Furstenberger G. A causal relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology. 153:2000;11-26
34. 2 activity and the expression of cyclooxygenase-2 through different mechanisms in mouse keratinocytes. Mol. Pharmacol. 59:2001;860-866
35. Subbaramaiah K., Norton L., Gerald W., Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 277:2000;18649-18657
36. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-612
37. Pierce J.H., Arnstein P., DiMarco E., Artrip J., Kraus M.H., Lonardo F., et al. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene. 6:1991;1189-1194
38. Kosaka T., Miyata A., Ihara H., Hara S., Sugimoto T., Takeda O., et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem. 221:1994;889-897
39. Xin J.H., Cowie A., Lachance P., Hassell J.A. Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells. Genes Develop. 6:1992;481-496
40. Dittmer J., Nordheim A. Ets transcription factors and human disease. Biochim. Biophys. Acta. 1377:1998;F1-F11
41. Howe L.R., Crawford H.C., Subbaramaiah K., Hassell J.A., Dannenberg A.J., Brown A.M. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J. Biol. Chem. 276:2001;20108-20115
42. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:1997;707-747
43. Sugimoto T., Haneda M., Sawano H., Isshiki K., Maeda S., Koya D., et al. Endothelin-1 induces cyclooxygenase-2 expression via nuclear factor of activated T-cell transcription factor in glomerular mesangial cells. J. Am. Soc. Nephrol. 12:2001;1359-1368
44. Iniguez M.A., Martinez-Martinez S., Punzon C., Redondo J.M., Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J. Biol. Chem. 275:2000;23627-23635
45. 2, EP2 and EP4 receptors. J. Biol. Chem. 278:2003;49954-49964
46. Inoue H., Nanayama T., Hara S., Yokoyama C., Tanabe T. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells. FEBS Lett. 350:1994;51-54
47. Xie W., Fletcher B.S., Andersen R.D., Herschman H.R. v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element. Mol. Cell. Biol. 14:1994;6531-6539
48. Xie W., Herschman H.R. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J. Biol. Chem. 271:1996;31742-31748
49. Subbaramaiah K., Cole P.A., Dannenberg A.J. Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms. Cancer Res. 62:2002;2522-2530
50. Deng W.G., Zhu Y., Wu K.K. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood. 103:2004;2135-2142
51. Motojima K. Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions. Cell Struct. Funct. 18:1993;267-277
52. 2 is a ligand for the adipocyte determination factor PPARgamma. Cell. 83:1995;803-812
53. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 83:1995;813-819
54. 2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int. 61:2002;1957-1967
55. Janabi N. Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Delta(12,14)(12,14)-prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages. J. Immunol. 168:2002;4747-4755
56. Yang W.L., Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 22:2001;1379-1383
57. Hu Z.W., Kerb R., Shi X.Y., Wei-Laver T., Hoffman B.B. Angiotensin II increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells. J. Pharmacol. Exp. Ther. 303:2002;563-573
58. Subbaramaiah K., Lin D.T., Hart J.C., Dannenberg A.J. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J. Biol. Chem. 276:2001;12440-12448
59. Bonazzi A., Mastyugin V., Mieyal P.A., Dunn M.W., Laniado-Schwartzman M. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J. Biol. Chem. 275:2000;2837-2844
60. Glinghammar B., Skogsberg J., Hamsten A., Ehrenborg E. PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 308:2003;361-368
61. 2 in rats. Toxicology. 126:1998;65-73
62. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274:1999;10911-10915
63. Leung W.K., To K.F., Ng Y.P., Lee T.L., Lau J.Y., Chan F.K., et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br. J. Cancer. 84:2001;335-339
64. Aggarwal BB, Vilcek J. Tumor necrosis factor: structure, function and mechanism of action. New York: Marcel Dekker Inc., 1992.
65. Shishodia S., Aggarwal B.B. Nuclear factor-kappa B activation: a question of life and death. J. Biochem. Mol. Biol. 35:2002;28-40
66. Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., Maniais T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J. 9:1995;899-909
67. Chen F., Castranova V., Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am. J. Pathol. 159:2001;387-397
68. Baeuerle P.A., Baltimore D. NF-kappa B: ten years after. Cell. 87:1996;13-20
69. Thanos D., Maniatis T. NF-κB: a lesson in family values. Cell. 80:1995;529-532
70. Baldwin A.S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-683
71. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18:1999;6853-6866
72. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J. Biol. Chem. 274:1999;27339-27342
73. Zandi E., Karin M. Bridging the gap: composition, regulation, and physiological function of the IκB kinase complex. Mol. Cell. Biol. 19:1999;4547-4551
74. Cohen L., Henzel W.J., Bauerle P.A. IκAP is a scaffold protein of the IκB kinase complex. Nature. 395:1998;292-296
75. D'Acquisto F., Iuvone T., Rombola L., Sautebin L., Di Rosa M., Carnuccio R. Involvement of NF-κB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett. 418:1997;175-178
76. Kojima M., Morisaki T., Izuhara K., Uchiyama A., Matsunari Y., Katano M., et al. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene. 19:2000;1225-1231
77. Liu S.F., Ye X., Malik A.B. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation. 100:1999;1330-1337
78. Yan X., Wu Xiao C., Sun M., Tsang B.K., Gibb W. Nuclear factor κB activation and regulation of cyclooxygenase type-2 expression in human amnion mesenchymal cells by interleukin-1β Biol. Reprod. 66:2002;1667-1671
79. Lee F.S., Hagler J., Chen Z.J., Maniatis T. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell. 88:1997;213-222
80. Schwenger P., Alpert D., Skolnik E.Y., Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκBα phosphorylation and degradation. Mol. Cell. Biol. 18:1998;78-84
81. Chen F., Demers L.M., Vallyathan V., Ding M., Lu Y., Castranova V., et al. Vanadate induction of NF-kappaB involves IkappaB kinase beta and SAPK/ERK kinase 1 in macrophages. J. Biol. Chem. 274:1999;20307-20312
82. Beyaert R., Cuenda A., Vanden Berghe W., Plaisance S., Lee J.C., Haegeman G., et al. The p38/ERK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 15:1996;1914-1923
83. Vanden Berghe W., Plaisance S., Boone E., De Bosscher K., Schmitz M.L., Fiers W., et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273:1998;3285-3290
84. Wang D., Baldwin A.J. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273:1998;29411-29416
85. Carter A.B., Knudtson K.L., Monick M.M., Hunninghake G.W. J. Biol. Chem. 274:1999;30858-30863
86. Angel P., Imagawa M., Chiu R., Stein B., Imbra R.J., Rahmsdorf H.J., et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. 49:1987;729-739
87. Van Straaten F., Muller R., Curran T., Van Beveren C., Verma I.M. Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein. Proc. Natl. Acad. Sci. U.S.A. 80:1983;3183-3187
88. Angel P., Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta. 1072:1991;129-157
89. Aronheim A., Zandi E., Hennemann H., Elledge S.J., Karin M. Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol. Cell. Biol. 17:1997;3094-3102
90. Wisdom R. AP-1: one switch for many signals. Exp. Cell Res. 253:1999;180-185
91. Nishizawa M., Kataoka K., Goto N., Fujiwara K., Kawai S. v-maf, a viral oncogene that encodes a "leucine zipper" motif. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7711-7715
92. Swaroop A., Xu J.Z., Pawar H., Jackson A., Skolnick C., Agarwal N. A conserved retina-specific gene encodes a basic motif/leucine zipper domain. Proc. Natl. Acad. Sci. U.S.A. 89:1992;266-270
93. Fujiwara K.T., Kataoka K., Nishizawa M. Two new members of the maf oncogene family, mafK and mafF, encode nuclear b-Zip proteins lacking putative trans-activator domain. Oncogene. 8:1993;2371-2380
94. Kataoka K., Noda M., Nishizawa M. Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and forms heterodimers with both Fos and Jun. Mol. Cell. Biol. 14:1994;700-712
95. Halazonetis T.D., Georgopoulos K., Greenberg M.E., Leder P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell. 55:1988;917-924
96. Kouzarides T., Ziff E. The role of the leucine zipper in the fos-jun interaction. Nature. 336:1988;646-651
97. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270:1995;16483-16486
98. Whitmarsh A.J., Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:1996;589-607
99. Deng T., Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature. 371:1994;171-175
100. Xie W., Herschman H.R. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J. Biol. Chem. 271:1996;31742-31748
101. Guo Y.S., Hellmich M.R., Wen X.D., Townsend C.M. Jr. Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells. J. Biol. Chem. 276:2001;22941-22947
102. Inoue H., Yokoyama C., Hara S., Tone Y., Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J. Biol. Chem. 270:1995;24965-24971
103. Williams S.C., Cantwell C.A., Johnson P.F. A family of C/EBP-related proteins capable of forming covalently linked leucine zipper dimers in vitro. Genes Develop. 5:1991;1553-1567
104. Chandrasekaran C., Gordon J.I. Cell lineage-specific and differentiation-dependent patterns of CCAAT/enhancer binding protein alpha expression in the gut epithelium of normal and transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8871-8875
105. O'Rourke J., Yuan R., DeWille J. CCAAT/enhancer-binding protein-delta (C/EBP-delta) is induced in growth-arrested mouse mammary epithelial cells. J. Biol. Chem. 272:1997;6291-6296
106. Flodby P., Liao D.Z., Blanck A., Xanthopoulos K.G.H., Hallstrorm I.P. Expression of the liver-enriched transcription factors C/EBP alpha, C/EBP beta, HNF-1, and HNF-4 in preneoplastic nodules and hepatocellular carcinoma in rat liver. Mol. Carcinogen. 12:1995;103-109
107. Cao Z., Umek R.M., McKnight S.L. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Develop. 9:1991;168-181
108. Hendricks-Taylor L.R., Darlington G.L. Inhibition of cell proliferation by C/EBP alpha occurs in many cell types, does not require the presence of p53 or Rb, and is not affected by large T-antigen. Nucl. Acids Res. 23:1995;4726-4733
109. Watkins P.J., Condreay J.P., Huber B.E., Jacobs S.J., Adams D.J. Impaired proliferation and tumorigenicity induced by CCAAT/enhancer-binding protein. Cancer Res. 56:1996;1063-1067
110. Huang J.H., Liao W.S. Induction of the mouse serum amyloid A3 gene by cytokines requires both C/EBP family proteins and a novel constitutive nuclear factor. Mol. Cell. Biol. 14:1994;4475-4484
111. Alam T., An M.R., Papaconstantinou J. Differential expression of three C/EBP isoforms in multiple tissues during the acute phase response. J. Biol. Chem. 267:1992;5021-5024
112. Ramji D.P., Vitelli A., Tronche F., Cortese R., Ciliberto G. The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucl. Acids Res. 21:1993;289-294
113. Yeh W., Cao Z., Classon M., McKnight S.L. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Develop. 9:1995;168-181
114. Kim Y., Fischer S.M. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues. J. Biol. Chem. 273:1998;27686-27694
115. Gorgoni B., Maritano D., Marthyn P., Righi M., Poli V. C/EBP beta gene inactivation causes both impaired and enhanced gene expression and inverse regulation of IL-12 p40 and p35 mRNAs in macrophages. J. Immunol. 168:2002;4055-4062
116. Nakajima T., Kinoshita S., Sasagawa T., Sasaki K., Naruto M., Kishimoto T., et al. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc. Natl. Acad. Sci. U.S.A. 90:1993;2207-2211
117. Engelman J.A., Lisanti M.P., Scherer P.E. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J. Biol. Chem. 273:1998;32111-32120
118. Cho Y.H., Lee C.H., Kim S.G. Potentiation of lipopolysaccharide-inducible cyclooxygenase 2 expression by C2-ceramide via c-Jun N-terminal kinase-mediated activation of CCAAT/enhancer binding protein beta in macrophages. Mol. Pharmacol. 63:2003;512-523
119. Ray L.B., Sturgill T.W. Characterization of insulin-stimulated microtubule-associated protein kinase. Rapid isolation and stabilization of a novel serine/threonine kinase from 3T3-L1 cells. J. Biol. Chem. 263:1988;12721-12727
120. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:2002;1911-1912
121. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71:1999;479-500
122. Pages G., Milanini J., Richard D.E., Berra E., Gothie E., Vinals F., et al. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann. NY Acad. Sci. 902:2000;187-200
123. Thomson S., Mahadevan L.C., Clayton A.L. MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction. Semin. Cell Develop. Biol. 10:1999;205-214
124. Coso O.A., Chiariello M., Kalinec G., Kyriakis J.M., Woodgett J., Gutkind J.S. Transforming G protein-coupled receptors potently activate JNK (SAPK). Evidence for a divergence from the tyrosine kinase signaling pathway. J. Biol. Chem. 270:1995;5620-5624
125. Arbabi S., Rosengart M.R., Garcia I., Maier R.V. Hypertonic saline solution induces prostacyclin production by increasing cyclooxygenase-2 expression. Surgery. 128:2000;198-205
126. 2 production by lipopolysaccharide-stimulated macrophages is not dependent on nuclear factor kappaB. J. Surg. Res. 113:2003;189-194
127. Chen W., Tang Q., Gonzales M.S., Bowden G.T. Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. Oncogene. 20:2001;3921-3926
128. Scherle P.A., Ma W., Lim H., Dey S.K., Trzaskos J.M. Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy. J. Biol. Chem. 275:2000;37086-37092
129. Pouliot M., Baillargeon J., Lee J.C., Cleland L.G., James M.J. Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. J. Immunol. 158:1997;4930-4937
130. Reiser C.O., Lanz T., Hofmann F., Hofer G., Rupprecht H.D., Goppelt-Struebe M. Lysophosphatidic acid-mediated signal-transduction pathways involved in the induction of the early-response genes prostaglandin G/H synthase-2 and Egr-1: a critical role for the mitogen-activated protein kinase p38 and for Rho proteins. Biochem. J. 330:1998;1107-1114
131. Ridley S.H., Dean J.L., Sarsfield S.J., Brook M., Clark A.R., Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett. 439:1998;75-80
132. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. Engl. J. Med. 342:2000;1946-1952
133. Kawamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412
134. Harris R.E., Alshafie G.A., Abou-Issa H., Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60:2000;2101-2103
135. Alshafie G.A., Abou-Issa H.M., Seibert K., Harris R.E. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol. Rep. 7:2000;1377-1381
136. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:2000;5599-5602
137. Fischer S.M., Lo H.H., Gordon G.B., Seibert K., Kelloff G., Lubet R.A., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinogen. 25:1999;231-240
138. Pentland A.P., Schoggins J.W., Scott G.A., Khan K.N., Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 20:1999;1939-1944
139. Chun K.-S., Kim S.H., Song Y.S., Surh Y.-J. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis. 25:2004;713-722
140. Niederberger E., Tegeder I., Vetter G., Schmidtko A., Schmidt H., Euchenhofer C., et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-κB. FASEB J. 15:2001;1622-1624
141. 2 in human head and neck xenograft tumors. Cancer Res. 62:2002;6706-6711
142. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., Masferrer J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:2002;625-631
143. Ostrowski J., Wocial T., Skurzak H., Bartnik W. Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors? Br. J. Cancer. 88:2003;1143-1151
144. Pegg A.E. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem. J. 234:1986;249-262
145. Fischer S.M., Conti C.J., Viner J., Aldaz C.M., Lubet R.A. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis. 24:2003;945-952
146. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275:2000;11397-11403
147. Grosch S., Tegeder I., Niederberger E., Brautigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15:2001;2742-2744
148. Badawi A.F., Eldeen M.B., Liu Y., Ross E.A., Badr M.Z. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res. 64:2004;1181-1189
149. Maier T.J., Schilling K., Schmidt R., Geisslinger G., Grosch S. Cyclooxygenase-2-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67:2004;1469-1478
150. Buttar N.S., Wang K.K., Leontovich O., Westcott J.Y., Pacifico R.J., Anderson M.A., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 122:2002;1101-1112
151. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94:2002;585-591
152. Harris R.E., Namboodiri K.K., Farrar W.B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 7:1996;203-205
153. Jacoby R.F., Cole C.E., Tutsch K., Newton M.A., Kelloff G., Hawk E.T., et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 60:2000;1864-1870
154. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 58:1998;5354-5360
155. Shiotani H., Denda A., Yamamoto K., Kitayama W., Endoh T., Sasaki Y., et al. Increased expression of cyclooxygenase-2 protein and 4-nitroquinoline-1- oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res. 61:2001;1451-1456
156. Rao C.V., Indranie C., Simi B., Manning P.T., Connor J.R., Reddy B.S. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 62:2002;165-170
157. Jang T.J., Jung H.G., Jung K.H., O M.K. Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int. J. Exp. Pathol. 83:2002;173-182
158. Abou-Issa H.M., Alshafie G.A., Seibert K., Koki A.T., Masferrer J.L., Harris R.E. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res. 21:2001;3425-3432
159. Hu P.J., Yu J., Zeng Z.R., Leung W.K., Lin H.L., Tang B.D., et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut. 53:2004;195-200
160. Wilgus T.A., Koki A.T., Zweifel B.S., Kusewitt D.F., Rubal P.A., Oberyszyn T.M. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol. Carcinogen. 38:2003;49-58
161. Orengo I.F., Gerguis J., Phillips R., Guevara A., Lewis A.T., Black H.S. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch. Dermatol. 138:2002;751-755
162. Diperna C.A., Bart R.D., Sievers E.M., Ma Y., Starnes V.A., Bremner R.M. Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J. Thorac. Cardiovasc. Surg. 126:2003;1129-1133
163. Dickens D.S., Cripe T.P. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J. Pediatr. Hematol. Oncol. 25:2003;709-714
164. Saukkonen K., Tomasetto C., Narko K., Rio M.C., Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of
165. Jacoby R.F., Seibert K., Cole C.E., Kelloff G., Lubet R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 60:2000;5040-5044
166. Wenger F.A., Kilian M., Achucarro P., Heinicken D., Schimke I., Guski H., et al. Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology. 2:2002;54-60